WMP
GNOM icon

Wealth Management Partners’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Wealth Management Partners’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$577K Buy
10,144
+4,558
+82% +$217K 0.14% 104
2026
Q1 		$244K Buy
+5,586
New +$258K 0.07% 135

Other funds holding GNOM

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

Wealth Management Partners's GNOM Position: Q2 2026 in Review

Wealth Management Partners increased its Global X Genomics & Biotechnology ETF (GNOM) stake by 82% in Q2 2026, buying an estimated $217K and bringing the position to 10,144 shares worth $577K. The position accounts for 0.14% of the portfolio, ranked #104.

Wealth Management Partners first reported a position in GNOM in Q1 2026 and has held it in 2 quarters since. 48 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

  • Wealth Management Partners held 10,144 shares of Global X Genomics & Biotechnology ETF worth $577K as of Q2 2026.
  • Wealth Management Partners bought 4,558 Global X Genomics & Biotechnology ETF shares in Q2 2026, an estimated $217K.
  • Global X Genomics & Biotechnology ETF made up 0.14% of Wealth Management Partners's portfolio in Q2 2026, its #104 holding.
  • Wealth Management Partners first reported a position in Global X Genomics & Biotechnology ETF in Q1 2026 and has held it in 2 quarters since.
  • 48 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on Wealth Management Partners's 13F filing for Q2 2026, filed 22 Jul 2026.